INTEGER HOLDINGS CORP

ITGR stock represents shares of Integer Holdings Corporation, a medical device contract manufacturer listed on the New York Stock Exchange. The company develops and produces components and finished devices for cardiac rhythm management, neuromodulation, and other medical markets. ITGR is not a diversified healthcare company but a supplier to original equipment manufacturers, so its business depends on relationships with medical device firms and the pace of their product launches.

Recent performance for ITGR depends on the latest trading activity, so the most accurate figure is the current quote and percentage change shown on this page. That data reflects the most recent close and any after-hours movement. For context, compare the day's move with the 52-week range and volume displayed alongside the price to see whether the change is meaningful relative to ITGR's normal trading range.

Valuation of ITGR is typically assessed using earnings-based and cash-flow-based multiples. A common starting point is the price-to-earnings ratio, which compares the share price with earnings per share. Investors also review enterprise value relative to EBITDA because ITGR carries debt. Comparing these multiples with medical device peers and with ITGR's own historical range helps frame whether the current valuation is in line with expectations.

Trading in ITGR outside regular U.S. market hours occurs in pre-market and after-hours sessions, when liquidity is generally thinner and spreads can be wider. Some brokers allow extended-hours orders, but execution is not guaranteed and prices may differ from the regular session. Investors should verify their broker's extended-hours rules and consider that overnight news can create larger price gaps when regular trading resumes.

For ITGR, useful metrics include revenue growth, organic growth excluding acquisitions, gross and operating margins, and adjusted EBITDA. Free cash flow matters because contract manufacturing is capital intensive, and net debt relative to EBITDA indicates leverage. Earnings per share and guidance updates also carry weight, since ITGR's results are tied to medical device demand and the timing of customer programs.

ITGR faces customer concentration risk, as a limited number of medical device companies account for a meaningful share of revenue. The business is also exposed to regulatory and quality compliance requirements, supply chain disruptions, and pricing pressure from large customers. Acquisitions add integration risk, and the company's debt load can amplify the impact of weaker operating results or higher interest costs.